PARZSWEEP : A NOVEL PARALLEL ALGORITHM FOR VOLUME RENDERING OF REGULAR DATASETS By

Lakshmy Ramaswamy,S. Bridges

Abstract:

What problem does this paper attempt to address?

The Predominant Proteins That React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight Between the Mammary Gland and Uterus in the Mouse and Rat.

Aliccia Bollig-Fischer,Archana Thakur,Yuan Sun,Jiusheng Wu,D Joshua Liao

DOI: https://doi.org/10.59566/ijbs.2012.8051

2012-01-01

Abstract:There are many estrogen receptor α (ERα) antibodies available but few of them target a rodent ERα. Using the MC-20 antibody raised against the C-terminus of mouse ERα, we show in this communication that in the mammary gland of female mice and rats, the wild type (wt) ERα was detected on immunoblots as a dominant protein only during lactation, and the protein was lactating specific as it migrated slightly faster than the 67-kD wt ERα in the uterus, likely due to a different phosphorylation status. In contrast, in the nulliparous, pregnant, involuting and involuted mammary glands, the dominant protein recognized by MC-20 was about 61-kD, which is dubbed herein as "MC-20 reactive protein" or MC20RP in abbreviation as its identity is unknown. Our results showed that it was not derived from proteolysis or de-phosphorylation of the 67-kD ERα and was unlikely to be translated from an ERα mRNA variant. Ovariectomy decreased the lactating specific wt ERα but increased the 61-kD MC20RP in the mammary tumors from MMTV-c-myc transgenic mice but these two proteins in the uterus were unaffected. The 61-kD MC20RP was decreased in the mammary tumors, compared with proliferating mammary glands, in estrogen-treated ACI rats. These results suggest that while the lactating specific wt ERα alone or together with the MC20RP may sustain lactation, the MC20RP may support proliferation of the mammary gland and some mammary tumors.
Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice

Yuxin Feng,David Manka,Kay-Uwe Wagner,Sohaib A. Khan

DOI: https://doi.org/10.1073/pnas.0706933104

IF: 11.1

2007-09-11

Proceedings of the National Academy of Sciences

Abstract:The estrogen receptor-α (ERα) is a critical transcription factor that regulates epithelial cell proliferation and ductal morphogenesis during postnatal mammary gland development. Tissue recombination and transplantation studies using the first generation of ERα knockout (ERKO) mice suggested that this steroid hormone receptor is required in the mammary stroma that subsequently exerts its effect on the epithelium through additional paracrine signaling events. A more detailed analysis revealed that ERKO mice produce a truncated ERα protein with detectable transactivation activity, and it is likely that this functional ERα variant has masked the biological significance of this steroid receptor in the mammary epithelium. In this article, we describe the generation a Cre-lox-based conditional knockout of the ERα gene to study the biological function of this steroid receptor in the epithelial compartment at defined stages of mammary gland development. The mouse mammary tumor virus (MMTV)-Cre-mediated, epithelial-specific ablation of exon 3 of the ERα gene in virgin mice severely impaired ductal elongation and side branching. The conditional knockout resulted in ablation of the ERα protein, and the progesterone receptor (PR), whose expression is under the control of ERα, was largely absent. The whey acidic protein (WAP)-Cre-mediated deletion of ERα during successive gestation cycles resulted in a loss of ductal side-branching and lobuloalveolar structures, ductal dilation, and decreased proliferation of alveolar progenitors. These abnormalities compromised milk production and led to malnourishment of the offspring by the second lactation. These observations suggest that ERα expression in the mammary epithelium is essential for normal ductal morphogenesis during puberty and alveologenesis during pregnancy and lactation.

multidisciplinary sciences
Effect of the p-Estrogen Receptor at Serine on Its Function and Breast Growth

Yuan Liang,Junhui Qin,Tiancheng Ma,Tong Yang,Zhenyu Ke,Ruian Wang

DOI: https://doi.org/10.1615/CritRevImmunol.2024052499

Abstract:Background: Estrogen receptor (ER) signaling plays an important role in the development and functional differentiation of the breast and participates in the process of breast cancer. Activated ER can affect various aspects of the cell's behavior, including proliferation, via modulating the expression of many downstream target genes. Phosphorylation is one of the activation pathways of ER. However, the relationship between estrogen receptor phosphorylation sites and breast development and carcinogenesis is not clear. Methods: Using Crisper-Cas9 gene editing technology, we constructed ER S309A mutant mice. Using carmine staining of the mammary gland of mice at different developmental stages, we examined the breast development of ER S309A mice. Using hematoxylin-eosin (HE) staining of vaginal smears of mice at the same time for 5 consecutive days, we measured the vaginal epithelial keratinocytes. Results: We established ER S309A mutant mice and observed breast defects in ER S309A mice. In addition, we observed decreased reproductive ability, and estrous cycle disorder in ER S309A mice. The number of vaginal epithelial keratino-cytes in the estrous cycle of ER S309A mice was decreased. Conclusion: These results suggest that the phosphorylation site of ER at Serine 309 is important for ER function and breast development.
Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor

SY Yeh,YC Hu,PH Wang,C Xie,QQ Xu,MY Tsai,ZH Dong,RS Wang,TH Lee,CS Chang

DOI: https://doi.org/10.1084/jem.20031233

2003-01-01

The Journal of Experimental Medicine

Abstract:Phenotype analysis of female mice lacking androgen receptor (AR) deficient (AR(-/-)) indicates that the development of mammary glands is retarded with reduced ductal branching in the prepubertal stages, and fewer Cap cells in the terminal end buds, as well as decreased lobuloalveolar development in adult females, and fewer milk-producing alveoli in the lactating glands. The defective development of AR(-/-) mammary glands involves the defects of insulin-like growth factor I-insulin-like growth factor I receptor and mitogen-activated protein kinase (MAPK) signals as well as estrogen receptor (ER) activity. Similar growth retardation and defects in growth factor-mediated Ras/Raf/MAPK cascade and ER signaling are also found in AR(-/-) MCF7 breast cancer cells. The restoration assays show that AR NH2-terminal/DNA-binding domain, but not the ligand-binding domain, is essential for normal MAPK function in MCF7 cells, and an AR mutant (R608K), found in male breast cancer, is associated with the excessive activation of MAPK. Together, our data provide the first in vivo evidence showing that AR-mediated MAPK and ER activation may play important roles for mammary gland development and MCF7 breast cancer cell proliferation.
Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats

Mônica Morais-Santos,Aryane E. B. Nunes,André G. Oliveira,Júnia Dayrell Moura-Cordeiro,Germán A. B. Mahecha,Maria Christina W. Avellar,Cleida A. Oliveira

DOI: https://doi.org/10.1371/journal.pone.0131901

IF: 3.7

2015-07-06

PLoS ONE

Abstract:Although the prostate is androgen-dependent, it is also influenced by estrogens, which act via the estrogen receptors ERα and ERβ. In the prostate, ERβ is highly expressed in the epithelium and appears to participate in the regulation of cell proliferation, apoptosis and differentiation. Evidence shows that ERβ is decreased in malignant prostate, suggesting that it plays an important role in protecting this tissue. Despite the relationship between reductions in ERβ and abnormal growth of the gland, little is known about the age-dependent variation of this receptor. Therefore, we aimed to investigate ERβ expression in the prostatic lobes of aging Wistar rats (3 to 24 months). Histopathological alterations, including hyperplasia, intraluminal concretions, nuclear atypia and prostate intraepithelial neoplasias (PIN), were observed in the prostates of aging rats. Epithelial proliferation led to cribriform architecture in some acini, especially in the ventral prostate (VP). In the VP, areas of epithelial atrophy were also observed. Furthermore, in the lateral prostate, there was frequent prostatitis. Immunohistochemistry revealed that the expression of ERβ is reduced in specific areas related to PIN, atrophic abnormalities and cellular atypia in the prostate epithelium of senile rats. Corroborating the involvement of the receptor with proliferative activity, the punctual reduction in ERβ paralleled the increase in cell proliferation especially in areas of PIN and nuclear atypies. The decrease in ERβ reactivity occurred in a hormonal milieu characterized by a constant concentration of estradiol and decreased plasmatic and tissue DHT. This paper is a pioneering study that reveals focal ERβ reduction in the prostate of aging rats and indicates a potential disorder in the ERβ pathway. These data corroborate previous data from humans and dogs that silencing of this receptor may be associated with premalignant or malignant conditions in the prostate.

multidisciplinary sciences
BRCA1-associated Mammary Tumorigenesis is Dependent on Estrogen Rather Than Progesterone Signaling

Marieke van de Ven,Xiaoling Liu,Eline van der Burg,Sjoerd Klarenbeek,Xanthippi Alexi,Wilbert Zwart,Fred Dijcks,Peter Bouwman,Jos Jonkers

DOI: https://doi.org/10.1002/path.5105

2018-01-01

Abstract:Hereditary breast cancers in BRCA1 mutation carriers are mostly estrogen receptor alpha (ER alpha)-negative and progesterone receptor (PR)-negative; however, hormone depletion via bilateral oophorectomy does result in a marked reduction in breast cancer risk, suggesting that BRCA1-associated breast tumorigenesis is dependent on hormone signaling. We used geneticaly engineered mouse models to determine the individual influences of ER alpha and PR signaling on the development of BRCA1-deficient breast cancer. In line with the human data, BRCA1-deficient mouse mammary tumors are ER alpha-negative, and bilateral ovariectomy leads to abrogation of mammary tumor development. Hormonal replacement experiments in ovariectomized mice showed that BRCA1-deficient mammary tumor formation is promoted by estrogen but not by progesterone. In line with these data, mammary tumorigenesis was significantly delayed by the selective ER alpha downregulator fulvestrant, but not by the selective PR antagonist Org33628. Together, our results illustrate that BRCA1-associated tumorigenesis is dependent on estrogen signaling rather than on progesterone signaling, and call into question the utility of PR antagonists as a tumor prevention strategy for BRCA1 mutation carriers. Copyright (c) 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α-Positive Mammary Adenocarcinomas

Priscilla A Furth,Weisheng Wang,Keunsoo Kang,Brendan L Rooney,Grace Keegan,Vinona Muralidaran,Justin Wong,Charles Shearer,Xiaojun Zou,Jodi A Flaws

DOI: https://doi.org/10.1016/j.ajpath.2022.09.008

Abstract:Age is a risk factor for human estrogen receptor-positive breast cancer, with highest prevalence following menopause. While transcriptome risk profiling is available for human breast cancers, it is not yet developed for prognostication for primary or secondary breast cancer development utilizing at-risk breast tissue. Both estrogen receptor α (ER) and aromatase overexpression have been linked to human breast cancer. Herein, conditional genetically engineered mouse models of estrogen receptor 1 (Esr1) and cytochrome P450 family 19 subfamily A member 1 (CYP19A1) were used to show that induction of Esr1 overexpression just before or with reproductive senescence and maintained through age 30 months resulted in significantly higher prevalence of estrogen receptor-positive adenocarcinomas than CYP19A1 overexpression. All adenocarcinomas tested showed high percentages of ER+ cells. Mammary cancer development was preceded by a persistent proliferative transcriptome risk signature initiated within 1 week of transgene induction that showed parallels to the Prosigna/Prediction Analysis of Microarray 50 human prognostic signature for early-stage human ER+ breast cancer. CYP19A1 mice also developed ER+ mammary cancers, but histology was more divided between adenocarcinoma and adenosquamous, with one ER- adenocarcinoma. Results demonstrate that, like humans, generation of ER+ adenocarcinoma in mice was facilitated by aging mice past the age of reproductive senescence. Esr1 overexpression was associated with a proliferative estrogen pathway-linked signature that preceded appearance of ER+ mammary adenocarcinomas.
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.

D B Lubahn,J S Moyer,T S Golding,J F Couse,K S Korach,O Smithies

DOI: https://doi.org/10.1073/pnas.90.23.11162

IF: 11.1

1993-12-01

Proceedings of the National Academy of Sciences

Abstract:Estrogen receptor and its ligand, estradiol, have long been thought to be essential for survival, fertility, and female sexual differentiation and development. Consistent with this proposed crucial role, no human estrogen receptor gene mutations are known, unlike the androgen receptor, where many loss of function mutations have been found. We have generated mutant mice lacking responsiveness to estradiol by disrupting the estrogen receptor gene by gene targeting. Both male and female animals survive to adulthood with normal gross external phenotypes. Females are infertile; males have a decreased fertility. Females have hypoplastic uteri and hyperemic ovaries with no detectable corpora lutea. In adult wild-type and heterozygous females, 3-day estradiol treatment at 40 micrograms/kg stimulates a 3- to 4-fold increase in uterine wet weight and alters vaginal cornification, but the uteri and vagina do not respond in the animals with the estrogen receptor gene disruption. Prenatal male and female reproductive tract development can therefore occur in the absence of estradiol receptor-mediated responsiveness.

multidisciplinary sciences
Embryonic lethality and defective mammary gland development of activator‐function impaired conditional knock‐in Erbb3 V943R mice

Kate Senger,Wenlin Yuan,Meredith Sagolla,Jonas Doerr,Brad Bolon,James Ziai,Kai‐Hui Sun,Soren Warming,Merone Roose‐Girma,Na Zhang,Lucinda Tam,Robert J. Newman,Subhra Chaudhuri,Aju Antony,Leonard D. Goldstein,Steffen Durinck,Bijay S. Jaiswal,Daniel Lafkas,Zora Modrusan,Somasekar Seshagiri

DOI: https://doi.org/10.1002/ggn2.10036

2020-12-05

Advanced Genetics

Abstract:ERBB3 is a pseudokinase domain‐containing member of the ERBB family of receptor tyrosine kinases (RTKs). Following ligand binding, ERBB receptors homo‐ or hetero‐dimerize, leading to a head‐to‐tail arrangement of the intracellular kinase domains, where the "receiver" kinase domain of one ERBB is activated by the "activator" domain of the other ERBB in the dimer. In ERBB3, a conserved valine at codon 943 (V943) in the kinase C‐terminal domain has been shown to be important for its function as an "activator" kinase in vitro. Here we report a knock‐in mouse model where we have modified the endogenous Erbb3 allele to allow for tissue‐specific conditional expression of Erbb3V943R (Erbb3CKI‐V943R). Additionally, we generated an Erbb3D850N (Erbb3CKI‐D850N) conditional knock‐in mouse model where the conserved aspartate in the DFG motif of the pseudokinase domain was mutated to abolish any potential residual kinase activity. While Erbb3D850N/D850N animals developed normally, homozygous Erbb3V943R/V943R expression during development resulted in embryonic lethality. Further, tissue specific expression of Erbb3V943R/V943R in the mammary gland epithelium following its activation using MMTV‐Cre resulted in delayed elongation of the ductal network during puberty. Single‐cell RNA‐seq analysis of Erbb3V943R/V943R mammary glands showed a reduction in a specific subset of fibrinogen‐producing luminal epithelial cells.
Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals

Priscilla A Furth,Weisheng Wang,Keunsoo Kang,Brendan L Rooney,Grace Keegan,Vinona Muralidaran,Xiaojun Zou,Jodi A Flaws

DOI: https://doi.org/10.1016/j.ajpath.2022.09.007

Abstract:Molecular-level analyses of breast carcinogenesis benefit from vivo disease models. Estrogen receptor 1 (Esr1) and cytochrome P450 family 19 subfamily A member 1 (CYP19A1) overexpression targeted to mammary epithelial cells in genetically engineered mouse models induces largely similar rates of proliferative mammary disease in prereproductive senescent mice. Herein, with natural reproductive senescence, Esr1 overexpression compared with CYP19A1 overexpression resulted in significantly higher rates of preneoplasia and cancer. Before reproductive senescence, Esr1, but not CYP19A1, overexpressing mice are tamoxifen resistant. However, during reproductive senescence, Esr1 mice exhibited responsiveness. Both Esr1 and CYP19A1 are responsive to letrozole before and after reproductive senescence. Gene Set Enrichment Analyses of RNA-sequencing data sets showed that higher disease rates in Esr1 mice were accompanied by significantly higher expression of cell proliferation genes, including members of prognostic platforms for women with early-stage hormone receptor-positive disease. Tamoxifen and letrozole exposure induced down-regulation of these genes and resolved differences between the two models. Both Esr1 and CYP19A1 overexpression induced abnormal developmental patterns of pregnancy-like gene expression. This resolved with progression through reproductive senescence in CYP19A1 mice, but was more persistent in Esr1 mice, resolving only with tamoxifen and letrozole exposure. In summary, genetically engineered mouse models of Esr1 and CYP19A1 overexpression revealed a diversion of disease processes resulting from the two distinct molecular pathophysiological mammary gland-targeted intrusions into estrogen signaling during reproductive senescence.
Mice lacking uterine enhancer of zeste homolog 2 have transcriptomic changes associated with uterine epithelial proliferation

Ana M Mesa,Jiude Mao,Manjunatha K Nanjappa,Theresa I Medrano,Sergei Tevosian,Fahong Yu,Jessica Kinkade,Zhen Lyu,Yang Liu,Trupti Joshi,Duolin Wang,Cheryl S Rosenfeld,Paul S Cooke

DOI: https://doi.org/10.1152/physiolgenomics.00098.2019

2020-02-01

Abstract:Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that suppresses gene expression. Previously, we developed a conditional null model where EZH2 is knocked out in uterus. Deletion of uterine EZH2 increased proliferation of luminal and glandular epithelial cells. Herein, we used RNA-Seq in wild-type (WT) and EZH2 conditional knockout (Ezh2cKO) uteri to obtain mechanistic insights into the gene expression changes that underpin the pathogenesis observed in these mice. Ovariectomized adult Ezh2cKO mice were treated with vehicle (V) or 17β-estradiol (E2; 1 ng/g). Uteri were collected at postnatal day (PND) 75 for RNA-Seq or immunostaining for epithelial proliferation. Weighted gene coexpression network analysis was used to link uterine gene expression patterns and epithelial proliferation. In V-treated mice, 88 transcripts were differentially expressed (DEG) in Ezh2cKO mice, and Bmp5, Crabp2, Lgr5, and Sprr2f were upregulated. E2 treatment resulted in 40 DEG with Krt5, Krt15, Olig3, Crabp1, and Serpinb7 upregulated in Ezh2cKO compared with control mice. Transcript analysis relative to proliferation rates revealed two module eigengenes correlated with epithelial proliferation in WT V vs. Ezh2cKO V and WT E2 vs. Ezh2cKO E2 mice, with a positive relationship in the former and inverse in the latter. Notably, the ESR1, Wnt, and Hippo signaling pathways were among those functionally enriched in Ezh2cKO females. Current results reveal unique gene expression patterns in Ezh2cKO uterus and provide insight into how loss of this critical epigenetic regulator assumingly contributes to uterine abnormalities.
Loss of ERβ Disrupts Gene Regulation in Primordial and Primary Follicles

Eun Bee Lee,V. Praveen Chakravarthi,Ryan Mohamadi,Vinesh Dahiya,Kevin Vo,Anamika Ratri,Patrick E. Fields,Courtney A. Marsh,M. A. Karim Rumi

DOI: https://doi.org/10.3390/ijms25063202

IF: 5.6

2024-03-12

International Journal of Molecular Sciences

Abstract:Loss of ERβ increases primordial follicle growth activation (PFGA), leading to premature ovarian follicle reserve depletion. We determined the expression and gene regulatory functions of ERβ in dormant primordial follicles (PdFs) and activated primary follicles (PrFs) using mouse models. PdFs and PrFs were isolated from 3-week-old Erβ knockout (Erβnull) mouse ovaries, and their transcriptomes were compared with those of control Erβfl/fl mice. We observed a significant (≥2-fold change; FDR p-value ≤ 0.05) deregulation of approximately 5% of genes (866 out of 16,940 genes, TPM ≥ 5) in Erβnull PdFs; ~60% (521 out of 866) of the differentially expressed genes (DEGs) were upregulated, and 40% were downregulated, indicating that ERβ has both transcriptional enhancing as well as repressing roles in dormant PdFs. Such deregulation of genes may make the Erβnull PdFs more susceptible to increased PFGA. When the PdFs undergo PFGA and form PrFs, many new genes are activated. During PFGA of Erβfl/fl follicles, we detected a differential expression of ~24% genes (4909 out of 20,743; ≥2-fold change; FDR p-value ≤ 0.05; TPM ≥ 5); 56% upregulated and 44% downregulated, indicating the gene enhancing and repressing roles of Erβ-activated PrFs. In contrast, we detected a differential expression of only 824 genes in Erβnull follicles during PFGA (≥2-fold change; FDR p-value ≤ 0.05; TPM ≥ 5). Moreover, most (~93%; 770 out of 824) of these DEGs in activated Erβnull PrFs were downregulated. Such deregulation of genes in Erβnull activated follicles may impair their inhibitory role on PFGA. Notably, in both Erβnull PdFs and PrFs, we detected a significant number of epigenetic regulators and transcription factors to be differentially expressed, which suggests that lack of ERβ either directly or indirectly deregulates the gene expression in PdFs and PrFs, leading to increased PFGA.

biochemistry & molecular biology,chemistry, multidisciplinary
ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer's disease

Aphrodite Demetriou,Birgitta Lindqvist,Heba G Ali,Mohamed M Shamekh,Silvia Maioli,Jose Inzunza,Mukesh Varshney,Per Nilsson,Ivan Nalvarte

DOI: https://doi.org/10.1101/2024.07.22.604543

2024-07-23

bioRxiv

Abstract:Menopausal loss of neuroprotective estrogen is thought to contribute to the sex differences in Alzheimer's disease (AD). Activation of estrogen receptor beta (ERβ) can be clinically relevant since it avoids the negative systemic effects of ERα activation. However, very few studies have explored ERβ-mediated neuroprotection in AD, and no information on its contribution to the sex differences in AD exists. In the present study we specifically explored the role of ERβ in mediating sex-specific protection against AD pathology in the clinically relevant App NL-G-F knock-in mouse model of amyloidosis, and if surgical menopause (ovariectomy) modulates pathology in this model. We treated male and female App NL-G-F mice with the selective ERβ agonist LY500307 and subset of the females was ovariectomized prior to treatment. Memory performance was assessed and a battery of biochemical assays were used to evaluate amyloid pathology and neuroinflammation. Primary microglial cultures from male and female wild-type and ERβ-knockout mice were used to assess ERβ's effect on microglial activation and phagocytosis. We find that ERβ activation protects against amyloid pathology and cognitive decline in male and female App NL-G-F mice. Ovariectomy increased soluble amyloid beta (Aβ) in cortex and insoluble Aβ in hippocampus, but had otherwise limited effects on pathology. We further identify that ERβ does not alter APP processing, but rather exerts its protection through amyloid scavenging that at least in part is mediated via microglia in a sex-specific manner. Combined, we provide new understanding to the sex differences in AD by demonstrating that ERβ protects against AD pathology differently in males and females, warranting reassessment of ERβ in combating AD.
ERβ mediates sex-specific protection in the mouse model of Alzheimer′s disease

Aphrodite Demetriou,Birgitta Lindqvist,Heba Galaa Ali,Mohamed Mohamed Shamekh,Silvia Maioli,Jose Inzunza,Mukesh Varshney,Ivan Nalvarte

DOI: https://doi.org/10.1101/2024.07.22.604543

2024-07-23

Abstract:Menopausal loss of neuroprotective estrogen is thought to contribute to the sex differences in Alzheimer′s disease (AD). Activation of estrogen receptor beta (ERβ) can be clinically relevant since it avoids the negative systemic effects of ERα activation. However, very few studies have explored ERβ-mediated neuroprotection in AD, and no information on its contribution to the sex differences in AD exists. In the present study we specifically explored the role of ERβ in mediating sex-specific protection against AD pathology in the clinically relevant knock-in mouse model of amyloidosis, and if surgical menopause (ovariectomy) modulates pathology in this model. We treated male and female mice with the selective ERβ agonist LY500307 and subset of the females was ovariectomized prior to treatment. Memory performance was assessed and a battery of biochemical assays were used to evaluate amyloid pathology and neuroinflammation. Primary microglial cultures from male and female wild-type and ERβ-knockout mice were used to assess ERβ′s effect on microglial activation and phagocytosis. We find that ERβ activation protects against amyloid pathology and cognitive decline in male and female . Ovariectomy increased soluble amyloid beta (Aβ) in cortex and insoluble Aβ in hippocampus, but had otherwise limited effects on pathology. We further identify that ERβ does not alter APP processing, but rather exerts its protection through amyloid scavenging that at least in part is mediated via microglia in a sex-specific manner. Combined, we provide new understanding to the sex differences in AD by demonstrating that ERβ protects against AD pathology differently in males and females, warranting reassessment of ERβ in combating AD.

Neuroscience
Conserved Genetic Networks Define Er-Alpha Status And Luminal And Basal Phenotypes In Mouse And Human Mammary Cancer: Added Value From The Mouse

aleksandra m michalowska,tinghu qiu,claudine kavanaugh,eva y h p lee,daniel medina,xiaoling xu,chuxia deng,john i powell,joanna h shih,jeffrey e green

IF: 11.2

2006-01-01

Cancer Research

Abstract:1551 Defining molecular similarities and differences between genetically engineered mouse models of mammary cancer and human breast cancer is critical to the further understanding of molecular mechanisms of oncogenesis and identifying models most relevant to human disease. One goal of this study was to use expression profiling in an attempt to determine whether several important, oncogenic pathway specific mouse models of mammary cancer could be classified according to the basal - luminal distinctions identified for human breast cancer. We demonstrate that all of the models studied in which p53 is mutated or functionally impaired and a BRCA1 mutant model cluster with human tumors in the basal-type category. All models in which the myc, ras, her2/neu and Polyoma middle T-antigen are driven by the MMTV promoter share molecular characteristics that cluster them with human luminal-type breast tumors. Interestingly, these models have been shown to lack ER-alpha expression (which is strongly associated with lack of GATA-3 expression in human breast cancers), but high expression of transcription factor GATA-3 is observed in our data for these models. A third group of mouse tumors include ER+ tumors arising from the p53fp/fp;Wap- cre model, which cluster with ER+ human tumors representing the luminal type A group. This new classification of GEM models provides a rational approach for further investigating the cellular origins of the different tumor classes and the appropriate use of the models in relation to the human tumor subclasses, especially pre-clinical testing. A second objective of this study was to determine whether mouse and human breast cancers share gene signatures based upon the status of ER expression. We have performed the first supervised comparison of gene expression profiles from mouse ER+ and ER- mammary tumors (generated by the mammary-specific conditional knock-out mutation of the p53 gene) with that of ER+ and ER- human breast tumors. Direct integration of gene expression levels from mouse tumors with that from human tumors (based upon ER expression) resulted in the most accurate classifier for ER status in human breast cancer, demonstrating the important added value of mouse data generated in a well-defined genetic background. The mouse-human ER classifier represents a set of genes co-expressed between mouse and human and can be placed into evolutionarily conserved networks based upon estrogen signaling. This approach reveals functionally conserved genes and networks across species important for cancer biology and identifying potential new therapeutic targets.
Mouse Models for BRCA1-associated Breast Cancer

R-H Wang,W Li,X Xu,C Deng

DOI: https://doi.org/10.1186/bcr662

2003-01-01

Breast Cancer Research

Abstract:Breast tumor suppressor gene 1 (BRCA1) is a well-known transcription regulator, mutations of which cause tumor formation in a tissue-specific manner. In the past years, we have studied functions of Brca1 in mouse models carrying a number of different mutations. We showed that impaired Brca1 function causes chromosome damages, failure of the G2/M cell cycle checkpoint, and centrosome amplification, leading to p53-dependent lethality. Our further analysis revealed that Brca1 also plays an important role in spindle checkpoint through regulating Mad2. We showed that mice carrying a targeted disruption of Brca1 in mammary epithelium developed mammary tumors at low frequency after long latency and the tumorigenesis was significantly accelerated in a p53+/- genetic background. Mammary tumors were highly diverse in histopathology and displayed extensive genetic/molecular alterations, including overexpression of ErbB2, c-myc, p27 and cyclin D1, and downregulation of p16. The most noticeable change is expression of estrogen receptor alpha (ERα). We showed that the absence of Brca1 resulted in increased expression of ERα in epithelial cells at pre-malignant stages and initiating tumors. However, expression of ERα was diminished in tumors of more advanced stages. This observation suggests that ERα-mediated signals are involved in tumorigenesis. Finally, we provided evidence that BRCA1 affects the MAPK pathway through interacting with estrogen/ERα signals, which may account for tissue-specific tumorigenesis.
A Role of Estrogen/erα Signaling in BRCA1-associated Tissue-Specific Tumor Formation

W Li,C Xiao,B K Vonderhaar,C-X Deng

DOI: https://doi.org/10.1038/sj.onc.1210527

IF: 8.756

2007-01-01

Oncogene

Abstract:Estrogen and its receptor alpha (ERα) have been implicated in the tissue-specific tumorigenesis associated with BRCA1 mutations. However, the majority of breast cancers developed in human BRCA1 mutation carriers are ERα-negative, challenging the link between BRCA1 and estrogen/ERα in breast cancer formation. Using a mouse model lacking the full-length form of BRCA1, here we show that ERα is highly expressed in the premalignant mammary gland and initiation stages of tumorigenesis, although its expression is gradually diminished during mammary tumor progression. We demonstrate that the absence of full-length BRCA1 increases sensitivity of cells to estrogen-induced extracellular signal-regulated kinase 1/2 phosphorylation and cyclin D1 expression. The absence of BRCA1 turns the proliferation of ERα-positive cells from a paracrine fashion to an autocrine or endocrine fashion. Consequently, BRCA1-mutant cells are sensitized to estrogen-induced cell proliferation in vitro and mammary tumorigenesis in vivo. These findings illustrate a molecular mechanism for estrogen/ERα signals in BRCA1-associated tissue-specific tumor formation, and identify several key elements in the estrogen/ERα-signaling cascade that can serve as potential therapeutic targets for BRCA1-associated tumorigenesis.
Estrogen receptor-alpha gene deficiency enhances androgen biosynthesis in the mouse Leydig cell

Benson T Akingbemi,Renshan Ge,Cheryl S Rosenfeld,Leslie G Newton,Dianne O Hardy,James F Catterall,Dennis B Lubahn,Kenneth S Korach,Matthew P Hardy

DOI: https://doi.org/10.1210/en.2002-220292

IF: 5.051

Endocrinology

Abstract:Leydig cells, which produce the primary male steroid hormone testosterone (T), express the two estrogen receptor (ER) subtypes, ERalpha and ERbeta, and have the capacity to convert testosterone to the natural estrogen 17beta-estradiol. Thus, Leydig cells are subject to estrogen action. The development of transgenic mice that are homozygous for targeted deletion of genes encoding the ER subtypes provides an opportunity to examine the role of estrogen in Leydig cell function. In this study androgen biosynthesis was analyzed in Leydig cells from mice that were homozygous for targeted deletion of the ERalpha gene (alphaERKO). T production by alphaERKO Leydig cells was 2-fold higher than that in wild-type (WT) cells. Serum T levels were accordingly higher in alphaERKO compared with WT mice (5.1 +/- 1.1 vs. 2.2 +/- 0.4 ng/ml; P </= 0.01) as were serum LH levels (1.31 +/- 0.3 vs. 0.45 +/- 0.08 ng/ml; P </= 0.01). Mice that were treated with the pure antiestrogen ICI 182,780 at 100 micro g/kg.d for 7 d, effectively abrogating ER-mediated activity, also had 2-fold elevations in the serum levels of LH (1.15 +/- 0.3 vs. 0.45 +/- 0.2 ng/ml) and T (4.3 +/- 1.1 vs. 2.2 +/- 0.2 ng/ml; P </= 0.01). Increased androgen biosynthesis by alphaERKO Leydig cells was associated with higher steroidogenic enzyme activity, especially of cytochrome P450 17alpha-hydroxylase/17-20 lyase (P450(17alpha)) and 17beta-hydroxysteroid dehydrogenase (17beta-HSD), as measured by conversion of radiolabeled steroid substrates to T or its precursors. The largest increases in enzymatic activity were observed for P450(17alpha) (423 +/- 45 pmol/min.10(6) cells in alphaERKO Leydig cells vs. 295 +/- 27 pmol/min.10(6) cells in WT cells; P < 0.01). Consistent with steroidogenic enzyme activity, the testis of alphaERKO mice expressed higher steady state mRNA levels for steroidogenic acute regulatory protein and two enzymes involved in androgen biosynthesis, P450(17alpha) and 17beta-HSD type III, as determined by semiquantitative RT-PCR. Compared with the controls, higher steady state mRNA levels for steroidogenic acute regulatory protein and P450(17alpha) were also measured in the testis of ICI 182,780-treated mice. In a second set of experiments estrogen administration reduced serum LH and T levels in WT controls, whereas alphaERKO mice were unaffected. Although exposure of WT and alphaERKO Leydig cells to estrogen in vitro did not affect androgen biosynthesis, incubation with ICI 182,780 reduced T production by WT, but not alphaERKO, Leydig cells. These observations indicate that abrogation of the ERalpha gene by targeted deletion or treatment with an antiestrogen increases Leydig cell steroidogenesis in association with elevations in the serum levels of LH, which presumably is the result of estrogen insensitivity at the level of the hypothalamus and/or pituitary gonadotropes. Furthermore, the decrease in T production by WT Leydig cells and not alphaERKO Leydig cells occasioned by incubation with ICI 182,780 suggests that of the ER subtypes, ERalpha has a regulatory role in Leydig cell steroidogenic function.
Abstract 5326: Selective deletion of estrogen receptor β in lung epithelium suppresses K-ras mutant lung tumorigenesis

Michael Joseph Clowers,Annamarie L. Thompson,Carlos Ignacio Rodriguez Reyna,Shanshan Deng,Seyed Javad Moghaddam

DOI: https://doi.org/10.1158/1538-7445.am2024-5326

IF: 11.2

2024-03-28

Cancer Research

Abstract:Although lung cancer is the most prolific cause of global cancer-related deaths, outcomes by sex have gained traction as a means to stratify patients and tailor therapies accordingly. In recent years, females have begun to shoulder a greater burden of lung cancer diagnoses, specifically within the lung adenocarcinoma (LUAD) subtype; conversely, mortality is worsened for males. However, other sex-dependent effects in lung cancer are harder to predict. For example, hormone replacement therapy for post-menopausal women has been shown to predict better survival in some cohorts while auguring worse outcomes in others. Similar controversy exists regarding menopausal status, gender affirming care, and castration/oophorectomy status. However, there is consensus that these differential effects relate to a patient's sex hormone composition. Estrogen, a sex hormone abounding in females, boasts well-described pro-tumor signaling in breast cancer. Unfortunately, its role in lung cancer remains elusive. Estrogen is reported to exert inflammatory properties in the lung environment, to drive immune function, and to induce proliferation of lung cancer cells. This functional antagonism has led to questions about how these compartment-specific effects are balanced. In the lung, estrogen signaling occurs mainly via estrogen receptor beta (ERβ), a nuclear hormone receptor highly expressed in lung tissue and lung tumors. ERβ is understudied relative to its sibling ERα, a well-known oncogene in breast cancer. While it is tempting to analogize ERα oncogene function to ERβ, the literature lacks consensus on the role of ERβ in lung cancer, with some authors classifying it as an oncogene and others as a tumor suppressor. In LUAD, Kras mutations encompass a quarter of driver mutations, and interaction of Kras with ERβ is understudied. Here, we tested the effects of genetic ablation of ERβ in a murine model of Kras mutant LUAD (KM-LUAD) termed CCSPCre/LSL-KrasG12D (CC-LR). Esr2 floxed mice were crossed with CC-LR mice to create a lung epithelial-specific conditional knockout of ERβ (LR/Esr2Δ/Δ). LR/Esr2Δ/Δ mice show significant decrease in tumor burden and total lung immune infiltration, indicating reduced tumor development and tumor-promoting inflammation. Of note, this effect manifests regardless of sex. RNA and protein-level analysis further suggest that ERβ deletion alters the balance of inflammatory transcription factors, resulting in skewing from STAT3- to NF-κB-driven inflammation and a net anti-tumor response. These data suggest that ERβ offers a promising early target in nascent KM-LUAD tumors with therapeutic intervention possible regardless of sex-specific effects. Acknowledgement: supported by NIH/NCI grant awarded to Seyed Javad Moghaddam (R01 CA225977); Michael J Clowers partly supported by NIH/NCI (F31 CA261121); Annamarie L Thompson supported by CPRIT Research Training Award (RP210028). Citation Format: Michael Joseph Clowers, Annamarie L. Thompson, Carlos Ignacio Rodriguez Reyna, Shanshan Deng, Seyed Javad Moghaddam. Selective deletion of estrogen receptor β in lung epithelium suppresses K-ras mutant lung tumorigenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5326.

oncology
ER β exerts multiple stimulative effects on human breast carcinoma cells

Yi-Feng Hou,Sheng-Tao Yuan,He-Cheng Li,Jiong Wu,Jin-Song Lu,Gang Liu,Li-Juan Lu,Zhen-Zhou Shen,Jian Ding,Zhi-Ming Shao

DOI: https://doi.org/10.1038/sj.onc.1207765

IF: 8.756

2004-01-01

Oncogene

Abstract:Recent studies of ERs in breast cancer have demonstrated the existence of ER β in addition to ER α . Some clinical data indicated that ER β had prognostic value for patient's survival, which suggested that ER β plays a key role in breast cancer development and metastasis. To test this hypothesis, we generated an ER β high-expression cell line by reintroduced human ER β cDNA into MDA-MB-435 cells. We demonstrated that ER β exerted multiple tumor-stimulative effects on human breast carcinoma cells both in vivo and in vitro . In in vitro studies, ER β was able to increase the proliferation and invasion of MDA-MB-435 cells significantly, while these effects were totally estradiol independent. Also, this stimulation was characterized by downregulation of p21 and upregulation of MMP-9, as well as transcriptional factor Est-1. In in vivo studies, we also demonstrated that ER β -transfected MDA-MB-435 cells grew much faster and had more pulmonary metastasis than mock or wild-type cells in nude mice. In ER β -transfected MDA-MB-435 xenografts, ER β caused significant reduction in p21 protein levels. Similar effects of ER β on MMP-9 and Ets-1 expression noted in vitro studies were also observed in the in vivo studies. These in vitro and in vivo studies indicated that ER β exerted multiple stimulative effects on breast cancer development and metastasis.

PARZSWEEP : A NOVEL PARALLEL ALGORITHM FOR VOLUME RENDERING OF REGULAR DATASETS By

The Predominant Proteins That React to the MC-20 Estrogen Receptor Alpha Antibody Differ in Molecular Weight Between the Mammary Gland and Uterus in the Mouse and Rat.

Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice

Effect of the p-Estrogen Receptor at Serine on Its Function and Breast Growth

Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor

Changes in Estrogen Receptor ERβ (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats

BRCA1-associated Mammary Tumorigenesis is Dependent on Estrogen Rather Than Progesterone Signaling

Overexpression of Estrogen Receptor α in Mammary Glands of Aging Mice Is Associated with a Proliferative Risk Signature and Generation of Estrogen Receptor α-Positive Mammary Adenocarcinomas

Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.

Embryonic lethality and defective mammary gland development of activator‐function impaired conditional knock‐in Erbb3 V943R mice

Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals

Mice lacking uterine enhancer of zeste homolog 2 have transcriptomic changes associated with uterine epithelial proliferation

Loss of ERβ Disrupts Gene Regulation in Primordial and Primary Follicles

ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer's disease

ERβ mediates sex-specific protection in the mouse model of Alzheimer′s disease

Conserved Genetic Networks Define Er-Alpha Status And Luminal And Basal Phenotypes In Mouse And Human Mammary Cancer: Added Value From The Mouse

Mouse Models for BRCA1-associated Breast Cancer

A Role of Estrogen/erα Signaling in BRCA1-associated Tissue-Specific Tumor Formation

Estrogen receptor-alpha gene deficiency enhances androgen biosynthesis in the mouse Leydig cell

Abstract 5326: Selective deletion of estrogen receptor β in lung epithelium suppresses K-ras mutant lung tumorigenesis

ER β exerts multiple stimulative effects on human breast carcinoma cells